By Josh Beckerman

A diabetes drug being developed by Sanofi (SNY) and Lexicon Pharmaceuticals Inc. (LXRX) received a tie vote from a U.S. Food and Drug Administration advisory panel.

Before the 8-8 vote, Lexicon shares had been halted all day.

The FDA isn't required to follow the advice of such advisory panels, but it generally does so. An FDA decision is expected by March 22.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

January 17, 2019 19:12 ET (00:12 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Lexicon Pharmaceuticals Charts.
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Lexicon Pharmaceuticals Charts.